Enhanced anti-inflammatory efficacy of a new piroxicam analogue through the MEK/ERK/NF-κB pathway in vitro and in vivo
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115100 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Jia-Qi Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricu…. Hauptthemen laut MEDLINE: Piroxicam, Colitis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Innovative Research Groups Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Piroxicam (PX) is potent and widely used for the treatment of inflammatory conditions. To develop active PX analogues with improved anti-inflammatory activity and minimized adverse effects, a series of PX analogues were designed and synthesized for enhancing anti-inflammatory activity. Among these derivatives, compound 12 exhibited superior NO-inhibitory ability with minimal cytotoxic effect in LPS-induced RAW 264.7 macrophage cells. Mechanistically, network pharmacology analysis and western blot assays revealed that the protective effect of compound 12 was attributed to the regulation of MEK/ERK signaling pathway inhibition in RAW 264.7 macrophages. Molecule docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS) assay indicated the direct interaction between compound 12 and MEK protein. Moreover, compound 12 demonstrated great inhibition of LPS-induced MEK activation and subsequent demonstrated great inhibition of LPS-induced NF-κB activation than compound PX. Furthermore, compared to compound PX, 10 mg/kg dose of compound 12 demonstrated improved mitigation of phenotypes in 2 % dextran sulfate sodium (DSS)-induced mouse colitis model. The inhibitory effect of compound 12 on MEK/ERK signaling pathway in colonic tissues was superior to that of compound PX. Overall, our study highlights compound 12 as a promising novel piroxicam analogue candidate for anti-inflammatory therapy, offering potential advancements in human inflammatory bowel disease (IBD) treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. Electronic address: wangwe…
- State Key Laboratory of Cellular Stress Biology, Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, Chin…
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. Electronic address: youzhi…
Förderung
- National Natural Science Foundation of China
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Innovative Research Groups Project of the National Natural Science Foundation of China
- Guangdong Special Support Program innovation team
Zitieren
APA
Luo, J. Q., Xu, L. L., Xiao, K. X., Lv, B. Y., Zhai, C. S., Wang, Q., Yang, W., Zhou, Z. D., Jin, Z., Wang, W., Du, D., & Tang, Y. Z. (2025). Enhanced anti-inflammatory efficacy of a new piroxicam analogue through the MEK/ERK/NF-κB pathway in vitro and in vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115100
Vancouver
Luo JQ, Xu LL, Xiao KX, Lv BY, Zhai CS, Wang Q, et al. Enhanced anti-inflammatory efficacy of a new piroxicam analogue through the MEK/ERK/NF-κB pathway in vitro and in vivo. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115100
BibTeX
@article{Luo2025,
author = {Luo, Jia-Qi and Xu, Ling-Ling and Xiao, Ke-Xin and Lv, Bing-Yi and Zhai, Chong-Shuo and Wang, Qi and Yang, Wei and Zhou, Zi-Dan and Jin, Zhen and Wang, Wei and Du, Dan and Tang, You-Zhi},
title = {Enhanced anti-inflammatory efficacy of a new piroxicam analogue through the MEK/ERK/NF-κB pathway in vitro and in vivo},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115100}
}
EUVIMED